Presentations by Program

Search by Program

Efficacy and safety of sulbactam-durlobactam (SUL-DUR) therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections in the open label Part B of the ATTACK phase 3 trial

Khurram Rana, David Altarac, Robin Isaacs, Subasree Srinivasan, Sarah McLeod, Gabrielle Poirier, Andrew Shorr and Keith Kaye (ECCMID, 2022)

Evaluation of the Pharmacokinetics/pharmacodynamics (PK/PD) of the Novel Diazabicyclooctane (DBO) ETX0462 Against Pseudomonas aeruginosa Infections, Including MDR Strains

John O'Donnell, Angela Tanudra, April Chen, Dan Hines, Ruben Tommasi, Alita Miller, and Thomas Durand-Reville (Microbe, 2021)

ETX0462 is a Novel PBP Inhibitor with Potent Activity against Recent, Global, Gram-Negative Clinical Isolates

Sarah McLeod, Michael Huband, Jennifer Thompson, and Alita Miller (Microbe, 2021)

The Novel, Non-β-lactam PBP Inhibitor, ETX0462, Has Potent Activity Against Biothreat Pathogens In Vitro and In Vivo

Ruben Tommasi, Henry Heine, George Drusano, Jason Cummings, Richard Slayden, Thomas Durand-Reville, John O’Donnell, and Alita Miller (Microbe, 2021)